Machine Learning

A new report reveals a stark disconnect. While 41% of employers view AI as a team member, most employees are not convinced, creating a major workplace rift.

Amid a 400% surge in ransomware targeting SAP, Onapsis and partners like Microsoft will tackle the security crisis driven by AI and cloud adoption.

Sarah Sommer, a deaf digital marketing exec, joins the Oberkotter Foundation board, blending personal insight with corporate strategy to advance hearing healthcare.

A new multi-year deal gives RNAi leader Alnylam access to Helix's vast genomic and clinical data, aiming to redefine the speed of drug discovery.

With data from 150M patients, SEQSTER's new platform promises to accelerate drug development, improve trial diversity, and make research-ready data a reality.

A new industry-first model allows health plans to pay only for successful HEDIS gap closures, eliminating financial risk amid rising quality pressures.

As AI-generated code introduces new risks, Snyk's partner awards highlight a channel-first strategy to tackle the 'speed paradox' in software security.

With a major new investment, Cognito Therapeutics is pushing its non-invasive light and sound therapy for Alzheimer's toward a 2027 market launch.

A new FDA program offers a lifeline for patients with rare ROSAH syndrome, accelerating Drug Farm's promising first-in-class therapy.

As burnout plagues radiology, Fujifilm unveils AI workflow solutions at HIMSS 2026 aimed at easing workloads and boosting hospital efficiency.

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

A new partnership sees Veritone's AI unlock The Washington Post's video vault, aiming to monetize history while protecting journalistic integrity.

A new report reveals why distributors are holding more stock, risking cash flow to battle volatility and win customers in a fiercely competitive market.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.